StockDuty ← Dashboard Oct 30, 2026 03:59 AM ET
SignalCorporate

Lilly outlines $91B-$92B 2026 revenue outlook as Medicare GLP-1 Bridge and Foundayo rollout expand access

Lilly's $91B–$92B 2026 revenue outlook cites Medicare GLP-1 Bridge and Foundayo rollout expanding access.

What happened: Eli Lilly outlined a 2026 revenue outlook and cited the Medicare GLP-1 Bridge and Foundayo rollout as expanding access, while reporting Q3 2026 results and raising full year guidance. Key numbers: 2026 revenue outlook of $91B to $92B. Why it matters: Management described Q3 as another quarter of solid execution, with raised full year guidance, pipeline progress and an expanded manufacturing footprint.
Eli Lilly outlined a 2026 revenue outlook and cited the Medicare GLP-1 Bridge and Foundayo rollout as expanding access, while reporting Q3 2026 results and raising full year guidance.
Management described Q3 as another quarter of solid execution, with raised full year guidance, pipeline progress and an expanded manufacturing footprint.
Sources